Portfolio Holdings Detail for ISIN IE00B3VWM098

Stock Name / Fund	iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc
Issuer	Blackrock
Entity holding fund	iShares VII Public Limited Company
Entity Type	Umbrella investment company with variable capital and having segregated liability between its funds
Entity LEI	549300Q7FFITMZ2PFZ28
ETF Ticker	CUS1(GBX) LSE
ETF Ticker	CUSS(USD) LSE
ETF Ticker	SXRG(EUR) F
ETF Ticker	CSUSS.MI(EUR) CXE
ETF Ticker	CSUSSz(USD) CXE
ETF Ticker	CUSS.LS(USD) CXE
ETF Ticker	CSUSS(EUR) ETF Plus
ETF Ticker	CUS1.L(GBP) LSE
ETF Ticker	CUSS.L(GBP) LSE

Holdings detail for NRIX

Show aggregate NRIX holdings

News associated with NRIX

Nurix Therapeutics, Inc. (NASDAQ:NRIX) Receives $28.87 Consensus Target Price from Brokerages

Nurix Therapeutics, Inc. (NASDAQ:NRIX – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the sixteen research firms that are covering the company, MarketBeat.com reports. Three investment analysts have rated the stock with a hold recommendation and thirteen have assigned a buy recommendation to the company. The average 12-month price target […] - 2025-08-27 02:54:56

18,716 Shares in Nurix Therapeutics, Inc. (NASDAQ:NRIX) Purchased by XTX Topco Ltd

XTX Topco Ltd purchased a new position in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX – Free Report) during the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 18,716 shares of the company’s stock, valued at approximately $222,000. Other institutional investors and hedge funds have also […] - 2025-08-13 04:26:46

TD Asset Management Inc Boosts Stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX)

TD Asset Management Inc increased its holdings in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX – Free Report) by 8.1% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 42,420 shares of the company’s stock after purchasing an additional 3,186 […] - 2025-08-05 04:34:52

HC Wainwright Lowers Nurix Therapeutics (NASDAQ:NRIX) Price Target to $34.00

Nurix Therapeutics (NASDAQ:NRIX – Get Free Report) had its target price cut by equities research analysts at HC Wainwright from $36.00 to $34.00 in a report issued on Monday,Benzinga reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s price objective would indicate a potential upside of 179.84% from the stock’s previous […] - 2025-07-16 04:26:52

Analysts Set Nurix Therapeutics, Inc. (NASDAQ:NRIX) Target Price at $30.18

Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX – Get Free Report) have received an average recommendation of “Moderate Buy” from the eighteen ratings firms that are currently covering the stock, Marketbeat.com reports. Three analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. The average 12 month […] - 2025-07-08 03:10:44

Nurix: European Medicines Agency Grants Orphan Drug Designation To Bexobrutideg

(RTTNews) - Nurix Therapeutics (NRIX) announced that the European Medicines Agency has granted Orphan Drug Designation to bexobrutideg for the treatment of lymphoplasmacytic lymphoma. Bexobrutideg is an orally bioavailable, brain penetrant degrader of Brutons tyrosine kinase whic - 2025-07-07 08:41:27

Sumitomo Mitsui Trust Group Inc. Sells 33,252 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX)

Sumitomo Mitsui Trust Group Inc. reduced its position in Nurix Therapeutics, Inc. (NASDAQ:NRIX – Free Report) by 4.2% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 755,970 shares of the company’s stock after selling 33,252 shares during the […] - 2025-07-04 05:13:03

Brokerages Set Nurix Therapeutics, Inc. (NASDAQ:NRIX) Price Target at $30.18

Nurix Therapeutics, Inc. (NASDAQ:NRIX – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the eighteen research firms that are covering the company, Marketbeat reports. Three investment analysts have rated the stock with a hold recommendation and fifteen have issued a buy recommendation on the company. The average 12-month target price […] - 2025-06-13 02:32:51

The Math Shows ESML Can Go To $48

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-06-05 07:20:56

ProShare Advisors LLC Acquires 7,261 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX)

ProShare Advisors LLC lifted its holdings in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX – Free Report) by 45.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 23,132 shares of the company’s stock after buying an additional 7,261 shares during the period. […] - 2025-05-28 05:09:01

Brokerages Set Nurix Therapeutics, Inc. (NASDAQ:NRIX) Price Target at $30.44

Nurix Therapeutics, Inc. (NASDAQ:NRIX – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the nineteen ratings firms that are currently covering the firm, Marketbeat.com reports. Three investment analysts have rated the stock with a hold recommendation and sixteen have issued a buy recommendation on the company. The average 1-year price […] - 2025-05-19 02:32:50

First Trust Advisors LP Acquires New Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX)

First Trust Advisors LP bought a new position in Nurix Therapeutics, Inc. (NASDAQ:NRIX – Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 135,903 shares of the company’s stock, valued at approximately $2,560,000. First Trust Advisors LP owned approximately […] - 2025-05-05 06:24:57

Invesco Ltd. Sells 361,360 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX)

Invesco Ltd. lessened its position in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX – Free Report) by 87.4% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 51,980 shares of the company’s stock after selling 361,360 shares during the quarter. Invesco Ltd.’s holdings […] - 2025-05-02 05:06:53

Norges Bank Purchases Shares of 318,800 Nurix Therapeutics, Inc. (NASDAQ:NRIX)

Norges Bank acquired a new position in Nurix Therapeutics, Inc. (NASDAQ:NRIX – Free Report) in the 4th quarter, Holdings Channel.com reports. The firm acquired 318,800 shares of the company’s stock, valued at approximately $6,006,000. Other institutional investors also recently bought and sold shares of the company. NEOS Investment Management LLC purchased a new stake in […] - 2025-04-10 05:34:49

Vanguard Group Inc. Has $81.87 Million Stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX)

Vanguard Group Inc. boosted its stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX – Free Report) by 8.3% during the 4th quarter, HoldingsChannel reports. The fund owned 4,345,266 shares of the company’s stock after acquiring an additional 333,452 shares during the quarter. Vanguard Group Inc. owned about 0.06% of Nurix Therapeutics worth $81,865,000 as of its most […] - 2025-04-10 04:44:59

Peek Under The Hood: DFAC Has 28% Upside

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-04-04 08:47:40

Nurix Therapeutics, Inc. (NASDAQ:NRIX) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX – Get Free Report) have received a consensus rating of “Moderate Buy” from the eighteen analysts that are presently covering the stock, MarketBeat.com reports. Three research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. The average 12-month price […] - 2025-03-27 04:38:49

US Bancorp DE Has $27,000 Stock Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX)

US Bancorp DE raised its holdings in Nurix Therapeutics, Inc. (NASDAQ:NRIX – Free Report) by 144.7% in the 4th quarter, HoldingsChannel reports. The fund owned 1,424 shares of the company’s stock after acquiring an additional 842 shares during the period. US Bancorp DE’s holdings in Nurix Therapeutics were worth $27,000 at the end of the […] - 2025-03-20 06:28:53

Bank of New York Mellon Corp Purchases 15,639 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX)

Bank of New York Mellon Corp lifted its position in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX – Free Report) by 8.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 190,905 shares of the company’s stock after buying an additional 15,639 shares during the […] - 2025-03-20 06:28:53

Leerink Partners Initiates Coverage on Nurix Therapeutics (NASDAQ:NRIX)

Leerink Partners began coverage on shares of Nurix Therapeutics (NASDAQ:NRIX – Free Report) in a report published on Monday morning, MarketBeat Ratings reports. The firm issued a market perform rating and a $16.00 price target on the stock. Several other equities analysts also recently commented on the company. HC Wainwright increased their price target on […] - 2025-03-18 04:30:53

Brokerages Set Nurix Therapeutics, Inc. (NASDAQ:NRIX) Target Price at $31.81

Nurix Therapeutics, Inc. (NASDAQ:NRIX – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the sixteen ratings firms that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a hold recommendation and fifteen have given a buy recommendation to the company. The average 1-year price objective […] - 2025-03-05 04:53:07

Rhumbline Advisers Acquires 12,315 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX)

Rhumbline Advisers raised its stake in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX – Free Report) by 13.5% during the fourth quarter, Holdings Channel reports. The firm owned 103,233 shares of the company’s stock after buying an additional 12,315 shares during the quarter. Rhumbline Advisers’ holdings in Nurix Therapeutics were worth $1,945,000 at the end of […] - 2025-03-04 06:10:55

Nurix Therapeutics (NASDAQ:NRIX) Stock Price Expected to Rise, Morgan Stanley Analyst Says

Nurix Therapeutics (NASDAQ:NRIX – Get Free Report) had its price objective lifted by analysts at Morgan Stanley from $16.00 to $17.00 in a research report issued to clients and investors on Monday,Benzinga reports. The firm presently has an “equal weight” rating on the stock. Morgan Stanley’s price target indicates a potential downside of 8.55% from […] - 2025-02-05 04:44:53

iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc NRIX holdings

Date	Number of NRIX Shares Held	Base Market Value of NRIX Shares	Local Market Value of NRIX Shares	Change in NRIX Shares Held	Change in NRIX Base Value	Current Price per NRIX Share Held	Previous Price per NRIX Share Held
2025-09-26 (Friday)	22,273	USD 198,898	USD 198,898
2025-09-25 (Thursday)	22,273	USD 185,534	USD 185,534	0	USD -8,241	USD 8.33	USD 8.7
2025-09-24 (Wednesday)	22,273	USD 193,775	USD 193,775
2025-09-17 (Wednesday)	22,129	USD 189,646	USD 189,646	0	USD 2,877	USD 8.57002	USD 8.44001
2025-09-16 (Tuesday)	22,129	USD 186,769	USD 186,769
2025-09-12 (Friday)	21,985	USD 198,744	USD 198,744
2025-09-11 (Thursday)	21,985	USD 202,262	USD 202,262

Share Trades of NRIX by Blackrock for IE00B3VWM098

Date	Action	Quantity	Market High	Market Low	Likely Trade Price	Likely Trade Value (Profit/Loss)	Average Price previous trades
2025-08-21	SELL	-72			9.650*		15.07 Profit of 1,085 on sale
2025-07-31	BUY	216			11.260*		15.12
2025-06-30	SELL	-144			11.390*		15.52 Profit of 2,235 on sale
2025-06-25	SELL	-72			11.620*		15.60 Profit of 1,123 on sale
2025-06-20	SELL	-144			11.490*		15.68 Profit of 2,259 on sale
2025-05-23	BUY	72			9.720*		16.38
2025-05-19	SELL	-72			9.510*		16.60 Profit of 1,195 on sale
2025-05-15	SELL	-216			9.460*		16.73 Profit of 3,613 on sale
2025-05-12	SELL	-72			10.180*		16.91 Profit of 1,218 on sale
2025-05-09	SELL	-72			9.500*		16.98 Profit of 1,223 on sale
2025-04-30	SELL	-72			11.530*		17.42 Profit of 1,254 on sale
2025-04-24	SELL	-144			11.520*		17.66 Profit of 2,543 on sale
2025-04-17	SELL	-72			10.240*		18.02 Profit of 1,298 on sale
2025-04-15	SELL	-216			9.820*		18.20 Profit of 3,932 on sale
2025-04-14	SELL	-216			9.850*		18.30 Profit of 3,952 on sale
2025-04-09	SELL	-288			9.600*		18.61 Profit of 5,358 on sale
2025-04-07	SELL	-504			9.720*		18.82 Profit of 9,484 on sale
2025-04-04	SELL	-720			9.690*		18.93 Profit of 13,626 on sale
2025-03-31	BUY	72			11.880*		19.21
2025-03-19	SELL	-144			13.900*		19.88 Profit of 2,862 on sale
2025-03-14	SELL	-432			13.590*		20.14 Profit of 8,698 on sale
2025-03-13	SELL	-146			13.190*		20.23 Profit of 2,954 on sale
2025-03-12	SELL	-2,482			14.540*		20.32 Profit of 50,427 on sale
2025-03-07	SELL	-146			13.860*		20.61 Profit of 3,010 on sale
2025-03-06	SELL	-219			14.050*		20.72 Profit of 4,537 on sale
2025-03-03	SELL	-73			14.190*		21.03 Profit of 1,535 on sale
2025-02-28	SELL	-438			15.450*		21.12 Profit of 9,250 on sale
2025-02-26	SELL	-73			17.060*		21.29 Profit of 1,554 on sale
2025-02-25	SELL	-219			16.470*		21.38 Profit of 4,681 on sale
2025-02-18	BUY	365			16.730*		21.79
2025-02-13	BUY	73			17.570*		22.04
2025-02-12	BUY	73			17.310*		22.14
2025-02-11	BUY	219			17.120*		22.24
2025-02-06	BUY	657			19.040*		22.48
2025-01-27	BUY	73			19.810*		23.14
2024-12-30	BUY	365			18.640*		23.58
2024-12-06	BUY	292			21.370*		23.81
2024-12-05	BUY	73			20.060*		23.94
2024-12-04	BUY	365			20.820*		24.05
2024-11-29	BUY	360			22.110*		24.35
2024-11-27	BUY	288			21.230*		24.62
2024-11-26	BUY	72			21.790*		24.75
2024-11-25	SELL	-42,323			21.820*		24.89 Profit of 1,053,561 on sale
2024-11-21	BUY	1,000			22.370*		25.18
2024-11-20	BUY	600			22.640*		25.32
2024-11-18	BUY	2,400			21.790*		25.70
2024-11-12	BUY	1,600			27.030*		25.61
2024-11-08	BUY	1,000			27.340*		25.48
2024-11-07	BUY	3,000			27.240*		25.35
2024-11-06	BUY	400			27.000*		25.21
2024-10-31	BUY	200			24.580*		25.37

Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of NRIX

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer